OpheliaWinter 2020Active☆Watch⊞Compare

Ophelia is one of 2138 Healthtech companies tracked from New York City, NY, USA; New York, NY, USA, on record since 2020. By capital raised it ranks in the long tail (ahead of 8% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Medication & support to beat opioid addiction from home

Ophelia helps people quit opioids without going to rehab. We offer online doctor’s visits, withdrawal medication prescriptions, and support for long-term recovery, using a protocol 6x more effective than most rehabs (2/3rds of which don't have doctors). More than 3 million Americans are addicted to opioids, but 80% are not getting help, due to jobs, families, and privacy concerns. Meanwhile, there's a proven treatment that increases survival rates by 600%, and it's low cost, discreet, and convenient. It's called MAT, and it looks like treatment for anxiety or depression: medication plus therapy. However, doctors need a special waiver to prescribe the medication, which fewer than 5% of them have, so it's difficult to get, and most people are buying it on the street. Sadly, drug dealers aren't doctors: every 11 minutes another American dies of an opioid overdose, now the #1 cause of death for Americans under 50. Ophelia is replacing rehab with telemedicine, using proven science and a consumer-first approach. The opioid treatment market in the U.S. is $15B, and 85% of opioid addicts have insurance that pays for it. We're treating roughly 400 patients with thousands more waiting. Zack started Ophelia after losing his girlfriend to an opioid overdose, who found it easier to get medication from a drug dealer than a doctor. We are raising money to help patients in waiting, grow our footprint, save lives, and earn venture-level returns for investors.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

No staged rounds to sequence.

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 8% of sector peers (real $). Modeled value above 8% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Ophelia is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Ophelia sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Ophelia, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.